

RNDr. Veronika Benson, Ph.D.

Born: January 26, 1976, Rakovník, Czechoslovakia

Positions and Employment

1999-2004 Researcher; Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2004-2006 Postdoctoral Fellows at National Cancer Institute, NIH, Bethesda, MD, USA
2006-2010 Researcher; Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2007-2013 Scientist; Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
2013- Group Leader, Dept. of Immunology and Gnotobiology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

Memberships and certifications

2001 Certificate in English issued by The British Council in Prague.
2003 Certificate of Specialist Overseeing Work with Radioactive Material issued by the State Department for Nuclear Safety of Czech Republic,
2007 Certificate for the Medical Profession without Professional Supervision (laboratory methods and drugs preparation) issued by the Ministry of Health of the Czech Republic,
2007-2009 member of European Hematology Association,
2008- member of Czech Immunological Society
2008- member of Consortium for Functional Glycomics

Teaching/ Education

2001-2004 Supervisor, Course of Microarray Technologies, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
2007- Ph.D. supervisor in the field of Molecular Biology and Genetics, Charles University, Faculty of Science, Prague
2009 Invited speaker at the 14th World Congress on Advances in Oncology, Loutraki, Greece
2013- External speaker at the Medical Faculty, Charles University of Prague in Pilsen; lectures: *The Tumor Microenvironment* and *The Use of Nanotechnologies in Contemporary Medicine*
2013- Assistant at Faculty of Biomedical Engineering, Czech Technical University, Kladno, Czech Republic
2014- Ph.D. supervisor in the field of Immunology, Charles University, Faculty of Science, Prague

Research interest

Nanoparticles as a diagnostic and therapeutic delivery tool; anti-tumor properties of Rho-GAP anti-oncogenes; miRNAs and cell migration; molecular biology of cancer and immune cells relationship.

Ongoing Research Support

ESF (European Social Fund) funding 05/01/13- 12/31/15 Title: *Integration of the team for research and development of new principles of nanotechnology in biomedicine for education and medical practice.*

Role: Co-PI and coordinator of key activity “Tumor Transformation Monitoring”; interdisciplinary project of the Czech Technical University at Kladno and cooperating European institutes.

Publications: 1 chapter in book; 12 publications in Congress Proceedings; 18 publications in journals; 31 communications in international and local conferences; h-index 7

List of publications within last 5 years (2009-2013):

1 Ullmannova-Benson V., Guan M., Zhou X., Tripathi V., Yang X.Y., Zimonjic D.B., Popescu N.C. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. *Leukemia*. 2009, 23(2):383-90.

2 Zimonjic DB, Ullmannova-Benson V, Factor VM, Thorgeirsson SS, Popescu NC. Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease. *Cancer Genet Cytogenet* 2009, 191(1):17-26.

3 Hulikova K, Benson V, Svoboda J, Sima P, Fiserova A. N-Acetyl-D-glucosamine-coated polyamidoamine dendrimer modulates antibody formation via natural killer cell activation. *Int Immunopharmacol* 2009, 9:792–799.

4 Otahalova E, Ullmannova-Benson V, Klamova H, Haskovec C. WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance. *Neoplasma* 2009, 56 (5):393-397.

5 Vannucci L, Stepankova R, Grobarova V, Kozakova H, Rossmann P, Klimesova K, Benson V, Sima P, Fiserova A, Tlaskalova-Hogenova H. Colorectal carcinoma: Importance of colonic environment for anti-cancer response and systemic immunity. *J Immunotoxicology* 2009; 6(4):217-26. Review.

6 Zimonjic DB, Zhou X, Lee JS, Ullmannova-Benson V, Tripathi V, Thorgeirsson SS, Popescu NC. Acquired genetic and functional alterations associated with transforming growth factor beta type I resistance in Hep3B human hepatocellular carcinoma cell line. *J Cell Mol Med* 2009, 13(9B):3985-92.

7 Benson V, Grobarova V, Richter J, Fiserova A. Glycosylation regulates NK cell-mediated effector function through PI3K pathway. *Int Immunol* 2010; 22(3):167-77.

8 Richter J, Benson V, Grobarova V, Svoboda J, Vencovsky J, Svobodova R, Fiserova A. CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. *Clin Immunol* 2010, 136(1):139-47.

9 Hulikova K, Svoboda J, Benson V, Grobarova V, Fiserova A. N-acetyl-D-glucosamine-coated polyamidoamine dendrimer promotes tumor-specific B cell responses via natural killer cell activation. *Int Immunopharmacol* 2011, 11(8):955-61.

10 Grobárová V, Benson V, Rozbeský D, Novák P, Cerný J. Re-evaluation of the involvement of NK cells and C-type lectin-like NK receptors in modulation of immune responses by multivalent GlcNAc-terminated oligosaccharides. *Immunology Letters* 2013, 156(1-2):110-7.